Inhalation Anesthetics Market - Growth, Trends, and Forecast (2020 - 2025)

The Market is Segmented by Type (Desflurane, Sevoflurane, Isoflurane, and Other Types), End User, and Geography.

Market Snapshot

Study Period:

2017-2025

Base Year:

2019

Fastest Growing Market:

Asia Pacific

Largest Market:

North America

CAGR:

3.7 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The inhalation anesthetics market is expected to register a CAGR of 3.7% during the forecast period. The market is expected to grow due to the increase in the number of surgeries being performed, globally. For instance, according to the annual estimates of Sedana Medical, there were about 4.5-7.5 million people ventilated and sedated worldwide in 2017. Furthermore, a rise in population pool, an increase in the number of the geriatric population prone to chronic diseases, growing demand for a lesser duration of hospitalization, and increasing accessibility to health services are some of the other factors responsible for the growth of the inhalation anesthetics market.

Inhalation anesthetics are also majorly used for accident care, where the intravenous route of administration is not an easy task in ambulatory settings. In emergency labors, rapid sequence induction of general anesthesia is performed with intubation of the trachea. Therefore, the increasing number of emergency cases all over the world is driving the inhalation anesthetics market.

As per the UN reports, the global population aged 60 years or over numbered 962 million in 2017, more than twice as large as in 1980, when there were 382 million older people worldwide. The number of older people is expected to double by 2050, projected to reach nearly 2.1 billion. However, side effects associated with the inhalation anesthetics, the lower adoption rate in case of inhaled anesthetics in certain surgical procedures, generic competition for almost all of the halogenated agents, and recent patent expiries are restraining the inhalation anesthetics market.

Scope of the Report

As per the scope of the report, inhalational anesthetics are used for the induction and maintenance of general anesthesia and sedation. The exact mechanisms by which they function are still unknown. The most common inhalational anesthetics are sevoflurane, desflurane, and nitrous oxide. Of these, sevoflurane is the most common due to its rapid onset of action and quick patient recovery.

Type
Desflurane
Sevoflurane
Isoflurane
Other Types
End User
Hospitals
Ambulatory Surgical Centers
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Sevoflurane Holds the Major Share in the Inhalation Anesthetics Market

Sevoflurane is the most widely used inhalational anesthetic, owing to its therapeutic advantages and low cost. Sevoflurane is an ether inhalation anesthetic agent with low pungency, a non-irritant odor, and a low blood, gas partition coefficient. It is found to be ideal for asthma patients or people with sensitized air passages. The drug has captured a major portion of the market, and it is expected to retain its position in the future as well.

The product is also marketed under the following names, Sojourn, Ultane, and Ultane PEN, in the United States, with Ultane being the most popular among all age groups. AbbVie is a key player of the market studied, and it sells Sevoflurane (sold under the trademarks Ultane and Sevorane) worldwide for human use.

To understand key trends, Download Sample Report

Asia-Pacific is Expected to be the Fastest Growing Market

Asia-Pacific is expected to expand at the fastest CAGR over the forecast period. The key factors contributing to its rapid growth include increasing population, public and private healthcare expenditure, availability of healthcare insurance for masses, and incidence of chronic diseases. Asia-Pacific is anticipated to have a significant growth due to the presence of high unmet needs, an increase in health awareness, a large population base, and an increase in the number of surgeries. Moreover, propelling medical tourism due to the availability of cost-efficient and advanced healthcare treatment options, compared to the other geographical regions, and increasing adoption of novel technologies are bolstering the growth of the inhalational anesthetics market in Asia-Pacific.

North America also witnessed a rapid increase in the number of diseases, such as obesity, cardiovascular disease, and different types of cancers, which contributed to the growth of the inhalation anesthetics market in the region.

To understand geography trends, Download Sample Report.

Competitive Landscape

Market players in the inhalation anesthetics market are focusing on the expansion of their product portfolios by adopting inorganic growth strategies, such as acquisitions, mergers, and partnerships. Only a few companies are coming forward with innovative technologies and new product launches. For example, in January 2019, Sandoz, a Novartis division, launched Desflurane Liquid for Inhalation, the first generic of Suprane, in the United States, as an inhalation agent for induction and maintenance of anesthesia for inpatient and outpatient surgery in adults, and for the maintenance of anesthesia for inpatient and outpatient surgery in pediatric patients.

You can also purchase parts of this report. Do you want to check out a section wise price list?

Table Of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Geriatric Population Prone to Chronic Diseases

      2. 4.2.2 Increasing Number of Emergency Cases and Surgical Interventions

      3. 4.2.3 Growing Demand for Lesser Duration in Hospitalization

      4. 4.2.4 Increasing Accessibility to Health Services and Surgeries

    3. 4.3 Market Restraints

      1. 4.3.1 Generic Competition for Almost All Halogenated Agents

      2. 4.3.2 Side-effects of Inhaler Anesthesia Drugs

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 Type

      1. 5.1.1 Desflurane

      2. 5.1.2 Sevoflurane

      3. 5.1.3 Isoflurane

      4. 5.1.4 Other Types

    2. 5.2 End User

      1. 5.2.1 Hospitals

      2. 5.2.2 Ambulatory Surgical Centers

      3. 5.2.3 Other End Users

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 AbbVie Inc.

      2. 6.1.2 Merck KGaA

      3. 6.1.3 Baxter International Inc.

      4. 6.1.4 Fresenius Kabi AG

      5. 6.1.5 Halocarbon Products Corporation

      6. 6.1.6 Hikma Pharmaceuticals PLC

      7. 6.1.7 Jiangsu Hengrui Medicine Co. Ltd

      8. 6.1.8 Lunan Pharmaceutical Group Co. Ltd

      9. 6.1.9 Piramal Enterprises Limited

      10. 6.1.10 Troikaa Pharmaceuticals Ltd

  7. *List Not Exhaustive
  8. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Related Reports